港股异动 | 中国飞鹤(6186.HK)涨超4% 年度纯利同比大增89%
格隆汇3月19日丨中国飞鹤(6186.HK)现报22.45港元,涨4.18%,暂成交1亿港元,最新总市值2005亿港元。中国飞鹤昨晚公布2020年度业绩称,期内,集团的总收益为185.925亿元(人民币,下同),同比增长35.5%;母公司拥有人应占年度溢利为74.369亿元,同比增长89%,每股基本盈利为0.83元,拟派末期息每股0.1586港元。公告称,集团的毛利率由2019年的70%增加至2020年的72.5%,主要因为集团的婴幼儿配方奶粉产品系列(在其产品中有相对较高的毛利率)于2020年的销售占比增加。此外,集团管理层已制定金额为350亿元的2023年销售目标及于2024年至2028年期间实现集团销售额15%的复合年增长率的目标。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.